ABSTRACT
Puerarin is a naturally occurring isoflavone C-glycoside,isolated from the root of Pueraria lobata,which has attracted extensive attention in the medical circles because of its various pharmacological effects,such as vasodilation,cardioprotection,neuroprotection,antioxidant,anticancer,anti-inflammation,alleviating pain,promoting bone formation,inhibiting alcohol intake,and attenuating insulin resistance. However,its low oral bioavailability has limited its clinical application. This review gives a comprehensive summary of the researches on physicochemical properties,pharmacokinetics( absorption,distribution,metabolism and excretion,pharmacokinetic parameters) in oral administration,and pharmaceutics research strategies of puerarin in recent years,and the in vivo behavior difference between multicomponent and single component environment was also summarized. The reasons( low water solubility,poor membrane permeability,short half-life,inhibition of P-gp efflux and first-pass metabolic effects of intestinal enzymes,etc.) for low bioavailability were concluded and the idea that multicomponent enviroment would affect the bioavailability was clarified. The aim of this review is to provide literature basis for the development of new dosage forms and new technologies for multivariate compound drug delivery system to improve the bioavailability of oral puerarin,and to propose ways to improve the bioavailability of BCS Ⅳ drugs derived from traditional Chinese medicine by fully enlarging the synergistic effect of multi-components or reasonably using the inhibitory effect between components.
Subject(s)
Administration, Oral , Biopharmaceutics , Isoflavones , PuerariaABSTRACT
OBJECTIVE:To provide reference for the selection and management of compound drugs. METHODS:The variet-ies and frequency of compound drugs recorded in the national drug reimbursement list and drug reimbursement list supplementary varieties in provinces (regions and municipalities) were statistically analyzed,and Spearman test method was used to conduct the correlation analysis for the variety and local economic development level. RESULTS:There were totally 126 varieties of compound drugs recorded in the national drug reimbursement list,covering 19 categories. The varieties of compound drugs in class B supple-mentary drug lists of 28 provinces (regions and municipalities) ranged from 19 to 50;for the supplementary lists of compound drugs in 24 provinces(regions and municipalities),the varieties ranged from 12 to 117. Almost 50% of the compound drugs were recorded in only 1 province(region and municipality),and most compound drugs recorded 1-4 time(s)in provinces(regions and municipalities). There was no significant relationship between the varieties number of supplementary compound drugs and the per capita GDP in a province(region and municipality)(P>0.05,r=-0.180). CONCLUSIONS:The supplementary variety of com-pound drugs in a region has little relationship with the local economic development level. The work progress of recoding the com-pound drugs varies a lot,with large differences in number and high dispersion. It is necessary to clarify the definition of compound drug at a national level,develop unified management policies,standardize the selection criteria for compound drugs and guarantee the clinical medication requirements of patients.
ABSTRACT
OBJECTIVE:To provide reference for the selection and management of compound drugs. METHODS:The variet-ies and frequency of compound drugs recorded in the national drug reimbursement list and drug reimbursement list supplementary varieties in provinces (regions and municipalities) were statistically analyzed,and Spearman test method was used to conduct the correlation analysis for the variety and local economic development level. RESULTS:There were totally 126 varieties of compound drugs recorded in the national drug reimbursement list,covering 19 categories. The varieties of compound drugs in class B supple-mentary drug lists of 28 provinces (regions and municipalities) ranged from 19 to 50;for the supplementary lists of compound drugs in 24 provinces(regions and municipalities),the varieties ranged from 12 to 117. Almost 50% of the compound drugs were recorded in only 1 province(region and municipality),and most compound drugs recorded 1-4 time(s)in provinces(regions and municipalities). There was no significant relationship between the varieties number of supplementary compound drugs and the per capita GDP in a province(region and municipality)(P>0.05,r=-0.180). CONCLUSIONS:The supplementary variety of com-pound drugs in a region has little relationship with the local economic development level. The work progress of recoding the com-pound drugs varies a lot,with large differences in number and high dispersion. It is necessary to clarify the definition of compound drug at a national level,develop unified management policies,standardize the selection criteria for compound drugs and guarantee the clinical medication requirements of patients.